• Explore /
  • Poster
  • / Combined assessment of metabolic response and tumor infiltrating lymphocytes as a predictor of outcomes following neoadjuvant therapy for HER2-positive breast cancer: Results from the randomized PREDIX HER2 trial.

Combined assessment of metabolic response and tumor infiltrating lymphocytes as a predictor of outcomes following neoadjuvant therapy for HER2-positive breast cancer: Results from the randomized PREDIX HER2 trial.

Abstract Poster

Authors

null

Alexios Matikas

Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

Alexios Matikas , Hemming Johansson , Per Grybäck , Judith Bjöhle , Tobias Lekberg , Hanna Fredholm , Balazs Acs , Ellinor Elinder , Erika Isaksson-Friman , Susanne Agartz , Mats Hellstrom , Ioannis Zerdes , Johan Hartman , Jonas C. S. Bergh , Thomas Hatschek , Theodoros Foukakis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Clinical Trial Registration Number

NCT02568839

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 593)

DOI

10.1200/JCO.2022.40.16_suppl.593

Abstract #

593

Poster Bd #

364

Abstract Disclosures

Similar Posters

First Author: Christian F. Singer

First Author: Yvonne Brandberg

First Author: Sandra M. Swain

First Author: Howard A. Burris III